Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Almorexant deal guarantees Swiss biotech $148 million, but another $409 million rides on approval, and the $2.7 billion for new indications is a bio-bucks poster number.
You may also be interested in...
GlaxoSmithKline/ Oxford BioTherapeutics Announce Alliance For Anti-Cancer Antibodies
Alliance is first OBT partnership with a big pharma; deal grants biotech double-digit royalties on products it develops through proof of concept.
GlaxoSmithKline/ Oxford BioTherapeutics Announce Alliance For Anti-Cancer Antibodies
Alliance is first OBT partnership with a big pharma; deal grants biotech double-digit royalties on products it develops through proof of concept.
2008 Deals Of The Year
Each week, "The Pink Sheet" presents commentary on some of the most interesting new business deals, contributed by the editors of the IN VIVO blog. As 2008 came to a close, the editors nominated the following transactions as their top deals of the year. Feeling moved to weigh in with your own favorite? 1Full write-ups of each deal and IVB's poll can be found at: http://invivoblog.blogspot.com/search/label/DOTY